Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jun 30;5:83. doi: 10.1038/s41746-022-00627-4

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 4 — a–d Surface plots of EIDD-1931 interactions with remdesivir (RDV) and baricitinib (BRT) in the validation interaction space, clinically actionable interaction space (black, solid line border) and the interaction space from the IDentif.AI-x analysis (black, dotted line border). All experiments were performed with N = 3 replicates, which were independently included in the surface construction. Black, round markers indicate an average %Inhibition of the replicates for each treatment. Adjusted R² (Adj R²) indicates goodness of the fit for each interaction surface. The experiments with SARS-CoV-2 B.1.351 variant (a, b), and B.1.617.2 variant (c, d) were performed in two independent sets. e %Inhibition against the propagated, original SARS-CoV-2 strain (bars with block filling), B.1.351 variant (bars with line filling) and B.1.617.2 variant (bars with cross lines filling) of 10% C_max EIDD-1931 in monotherapy (green) and in a combination with RDV and BRT at two concentration ratios: the ratio dictated by the C_max values of the drugs (C_max ratio; pink) and the ratio tested in the IDentif.AI-x experimental set (OACD ratio; purple). Black markers indicate individual data points. Error bars represent propagated standard deviation (s.d). Of note, this propagated s.d. did not arise from the replicates’ spread, but from plate-to-plate variation (s.d. of the controls). No statistically significant difference was detected with Kruskal–Wallis test when followed by Dunn’s post hoc test.